Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.
A new NINDS and NIMH grant program will provide up to $5 million in grants to develop scalable assays for analysis of molecular and cellular events in neurons related to brain functioning.
NINDS and Coriell Institute will continue to work together to expand a biorepository of clinical data and human samples that will facilitate genetic research into neurological conditions.
Although iZumi does not have a license to Kyoto iPSC patents, the collaboration builds upon other seminal iPSC IP it recently licensed from Bayer. The Kyoto deal may also help the company better define iZumi's stake in what is shaping up to be a complicated IP landscape surrounding the technology.
NHLBI plans to launch next month the prospectively designed, randomized-controlled study, called Clarification of Optimal Anticoagulation through Genetics trial, which will follow 1,200 patients to see if PGx-guided dosing is clinically useful.
